Study finds women disproportionally absent from clinical trials leadership
Even as women have gained ground in oncology, they remain under-represented as leaders of phase III clinical trials, MD Anderson researchers have found.
A team led by author Emma Holliday, M.D., assistant professor of Radiation Oncology, published its research this month in JAMA Oncology, reporting that of 598 Phase III cancer studies published between 2003 and 2018, only 107, or 17.9 percent, had female corresponding authors.<...
Triple combination therapy with nivolumab is feasible for AML, MDS patients
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...
Moon Shot confronts challenges of multiple cancers driven by HPV
According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...
Study defines genetic pathway for hard-to-treat form of lymphoma
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET inhibitors for treating a difficult-to-treat form of lymphoma.
Research findings were published online in Science Translational Medicine.
The study, led by Michael Green, Ph.D., assistant professor of Lymphoma & Myeloma, showed that transcription factor 4 (TCF4) is the most frequent...
